Pharminent

Sandoz secures fourth biosimilar approval in Europe with Rixathon

Sandoz, a division of Swiss firm Novartis, has announced that the European Commission has approved its biosimilar Rixathon for the same indications as its reference product rituximab.
These indications include the treatment of blood cancers such as non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia, and immunological disorders including rheumatoid arthritis, granulomatosis with polgyangitis and microscopic polyangitis.
read more http://www.pharmafile.com/news/514404/sandoz-secures-fourth-biosimilar-approval-europe-rixathon

Filed under: Biosimilar